Drug Trial Radar · NCT05522868
SB17170 Phase 1 Clinical Trial in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 17, 2022
Primary completion
Jun 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- SPARK BiopharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 Open-label, multicenter, dose escalation, dose expansion study
Conditions
- Solid Tumor
Interventions
SB17170Drug
SB17170 capsules, Oral administration 21days/cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of SB17170Time frame: At the end of Cycle 1 (each cycle is 21 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.